You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTrihexyphenidyl
Accession NumberDB00376  (APRD00070)
TypeSmall Molecule
GroupsApproved
DescriptionOne of the centrally acting muscarinic antagonists used for treatment of parkinsonian disorders and drug-induced extrapyramidal movement disorders and as an antispasmodic. [PubChem]
Structure
Thumb
Synonyms
(RS)-1-cyclohexyl-1-phenyl-3-(1-piperidyl)propan-1-ol
Apo-trihex
Benzhexol Hydrochloride
Trihexifenidilo
Trihexyphenidyl
Trihexyphénidyle
Trihexyphenidylum
External Identifiers
  • Win 511
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aparkane Tab 2mgtablet2 mgoralIcn Canada Ltd.1973-12-312005-04-26Canada
Aparkane Tab 5mgtablet5 mgoralIcn Canada Ltd.1973-12-312005-04-26Canada
Artane Elx 2mg/5mlelixir2 mgoralLederle Cyanamid Canada Inc.1967-12-311999-08-12Canada
Artane Tab 2mgtablet2 mgoralLederle Cyanamid Canada Inc.1951-12-311999-04-12Canada
Artane Tab 5mgtablet5 mgoralLederle Cyanamid Canada Inc.1951-12-311997-01-14Canada
Novo-hexidyl 2mgtablet2 mgoralNovopharm Limited1968-12-312005-08-10Canada
Novo-hexidyl 5mgtablet5 mgoralNovopharm Limited1967-12-312005-08-10Canada
Nu-trihexyphenidyltablet5 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-trihexyphenidyltablet2 mgoralNu Pharm IncNot applicableNot applicableCanada
PMS Trihexyphenidyltablet5 mgoralPharmascience Inc1987-12-31Not applicableCanada
PMS-trihexyphenidyltablet2 mgoralPharmascience Inc1987-12-31Not applicableCanada
PMS-trihexyphenidyl Elx 0.4mg/mlelixir0.4 mgoralPharmascience Inc1996-10-16Not applicableCanada
Trihexyphen 5 Tab 5mgtablet5 mgoralPro Doc Limitee1982-12-312010-07-13Canada
Trihexyphen Tab 2mgtablet2 mgoralPro Doc Limitee1982-12-312010-07-13Canada
Trihexyphenidyltablet2 mgoralAa Pharma Inc1982-12-31Not applicableCanada
Trihexyphenidyltablet5 mgoralAa Pharma Inc1982-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Trihexyphenidyl Hydrochloridetablet2 mg/1oralRising Pharmaceuticals, Inc.2010-11-17Not applicableUs
Trihexyphenidyl Hydrochloridetablet2 mg/1oralRichmond Pharmaceuticals, Inc.1998-12-24Not applicableUs
Trihexyphenidyl Hydrochloridetablet2 mg/1oralActavis Pharma, Inc.1987-11-01Not applicableUs
Trihexyphenidyl Hydrochloridetablet5 mg/1oralREMEDYREPACK INC.2014-08-26Not applicableUs
Trihexyphenidyl Hydrochloridesolution2 mg/5mLoralPharmaceutical Associates, Inc.1997-05-15Not applicableUs
Trihexyphenidyl Hydrochloridetablet2 mg/1oralREMEDYREPACK INC.2013-05-10Not applicableUs
Trihexyphenidyl Hydrochloridetablet5 mg/1oralREMEDYREPACK INC.2011-09-20Not applicableUs
Trihexyphenidyl Hydrochloridetablet5 mg/1oralClinical Solutions Wholesale1998-12-24Not applicableUs
Trihexyphenidyl Hydrochloridetablet5 mg/1oralQualitest Pharmaceuticals1998-12-24Not applicableUs
Trihexyphenidyl Hydrochloridetablet2 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Trihexyphenidyl Hydrochloridetablet5 mg/1oralNatco Pharma Limited Pharma Division2010-10-07Not applicableUs
Trihexyphenidyl Hydrochloridetablet5 mg/1oralRichmond Pharmaceuticals, Inc.1998-12-24Not applicableUs
Trihexyphenidyl Hydrochloridetablet5 mg/1oralActavis Pharma, Inc.1987-11-01Not applicableUs
Trihexyphenidyl Hydrochloridetablet5 mg/1oralRising Pharmaceuticals, Inc.2010-11-17Not applicableUs
Trihexyphenidyl Hydrochloridetablet5 mg/1oralWest ward Pharmaceutical Corp2000-02-16Not applicableUs
Trihexyphenidyl Hydrochloridetablet5 mg/1oralREMEDYREPACK INC.2013-05-29Not applicableUs
Trihexyphenidyl Hydrochloridetablet2 mg/1oralAmerican Health Packaging2010-01-12Not applicableUs
Trihexyphenidyl Hydrochloridetablet5 mg/1oralREMEDYREPACK INC.2011-03-10Not applicableUs
Trihexyphenidyl Hydrochloridetablet2 mg/1oralGolden State Medical Supply, Inc.2000-11-14Not applicableUs
Trihexyphenidyl Hydrochloridetablet2 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1998-02-06Not applicableUs
Trihexyphenidyl Hydrochloridetablet5 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Trihexyphenidyl Hydrochloridetablet5 mg/1oralTYA Pharmaceuticals2010-11-17Not applicableUs
Trihexyphenidyl Hydrochloridetablet5 mg/1oralREMEDYREPACK INC.2013-03-27Not applicableUs
Trihexyphenidyl Hydrochloridetablet2 mg/1oralCardinal Health1987-11-01Not applicableUs
Trihexyphenidyl Hydrochloridetablet2 mg/1oralCarilion Materials Management1987-11-01Not applicableUs
Trihexyphenidyl Hydrochloridetablet2 mg/1oralWest ward Pharmaceutical Corp2000-02-16Not applicableUs
Trihexyphenidyl Hydrochloridetablet2 mg/1oralREMEDYREPACK INC.2014-04-04Not applicableUs
Trihexyphenidyl Hydrochloridetablet5 mg/1oralAmerican Health Packaging2010-01-12Not applicableUs
Trihexyphenidyl Hydrochloridetablet2 mg/1oralREMEDYREPACK INC.2012-03-14Not applicableUs
Trihexyphenidyl Hydrochloridetablet5 mg/1oralGolden State Medical Supply, Inc.2000-11-14Not applicableUs
Trihexyphenidyl Hydrochloridetablet5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1998-02-06Not applicableUs
Trihexyphenidyl Hydrochloridetablet5 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Trihexyphenidyl Hydrochloridetablet2 mg/1oralAvera Mc Kennan Hospital2015-08-17Not applicableUs
Trihexyphenidyl Hydrochloridesolution2 mg/5mLoralMikart, Inc.1999-10-04Not applicableUs
Trihexyphenidyl Hydrochloridetablet2 mg/1oralClinical Solutions Wholesale1998-12-24Not applicableUs
Trihexyphenidyl Hydrochloridetablet2 mg/1oralQualitest Pharmaceuticals1998-12-24Not applicableUs
Trihexyphenidyl Hydrochloridetablet2 mg/1oralREMEDYREPACK INC.2014-04-18Not applicableUs
Trihexyphenidyl Hydrochloridetablet2 mg/1oralNatco Pharma Limited Pharma Division2010-10-07Not applicableUs
Trihexyphenidyl Hydrochloridetablet5 mg/1oralREMEDYREPACK INC.2012-10-01Not applicableUs
Trihexyphenidyl Hydrochloridesyrup2 mg/5mLoralVersa Pharm Incorporated2001-03-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ACAAtlantic
AcamedMedifive
AltantPanbiotic
ArtaneSanofi Aventis
ArtineThe Central
AtanNewai Chem
BenzhexolJohnson
BenzoxLi Ta
BexolIntas
BroflexAlliance
CyclodolGrindeks
DyskinilCrescent
Ea TenHeng Hsin
HexymerMersifarma
HipokinonPsicofarma
LahexyLa Pharmaceuticals
PacitaneWyeth
PakisonalTakata Seiyaku
ParalesPsyco Remedies
ParcisolMilve
PargitanNevada Pharma
ParkinMicro Synapse
ParkinaneEisai
ParkinesTowa Yakuhin
ParkinidylCCPC
ParkisanBalkanpharma
ParkitaneSun
ParkizolHikma
TonarilChile
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Trihexyphenidyl Hydrochloride
Thumb
  • InChI Key: QDWJJTJNXAKQKD-UHFFFAOYNA-N
  • Monoisotopic Mass: 337.217242358
  • Average Mass: 337.927
DBSALT000448
Categories
UNII6RC5V8B7PO
CAS number144-11-6
WeightAverage: 301.4662
Monoisotopic: 301.240564619
Chemical FormulaC20H31NO
InChI KeyInChIKey=HWHLPVGTWGOCJO-UHFFFAOYSA-N
InChI
InChI=1S/C20H31NO/c22-20(18-10-4-1-5-11-18,19-12-6-2-7-13-19)14-17-21-15-8-3-9-16-21/h1,4-5,10-11,19,22H,2-3,6-9,12-17H2
IUPAC Name
1-cyclohexyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol
SMILES
OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropylamines. These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by an propan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylpropylamines
Direct ParentPhenylpropylamines
Alternative Parents
Substituents
  • Phenylpropylamine
  • Aralkylamine
  • Piperidine
  • Tertiary alcohol
  • 1,3-aminoalcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationIndicated for the treatment of parkinson's disease and extrapyramidal reactions caused by drugs.
PharmacodynamicsTrihexyphenidyl is an anticholinergic used in the symptomatic treatment of all etiologic groups of parkinsonism and drug induced extrapyramidal reactions (except tardive dyskinesia). Trihexyphenidyl possesses both anticholinergic and antihistaminic effects, although only the former has been established as therapeutically significant in the management of parkinsonism.
Mechanism of actionTrihexyphenidyl is a selective M1 muscarinic acetylcholine receptor antagonist. It is able to discriminate between the M1 (cortical or neuronal) and the peripheral muscarinic subtypes (cardiac and glandular). Trihexyphenidyl partially blocks cholinergic activity in the CNS, which is responsible for the symptoms of Parkinson's disease. It is also thought to increase the availability of dopamine, a brain chemical that is critical in the initiation and smooth control of voluntary muscle movement.
Related Articles
AbsorptionTrihexyphenidyl is rapidly absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life3.3-4.1 hours
ClearanceNot Available
ToxicitySymptoms of overdose include mydriasis, dryness of mucous membranes, red face, atonic states of bowels and bladder, and hyperthermia in high doses. Central consequences are agitation, confusion, and hallucinations. An untreated overdose may be fatal, particular in children. Premortal signs are respiratory depression and cardiac arrest.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier+0.9523
Caco-2 permeable+0.6707
P-glycoprotein substrateSubstrate0.6943
P-glycoprotein inhibitor IInhibitor0.5993
P-glycoprotein inhibitor IINon-inhibitor0.7561
Renal organic cation transporterInhibitor0.7563
CYP450 2C9 substrateNon-substrate0.8256
CYP450 2D6 substrateNon-substrate0.7655
CYP450 3A4 substrateNon-substrate0.5746
CYP450 1A2 substrateNon-inhibitor0.9187
CYP450 2C9 inhibitorNon-inhibitor0.9126
CYP450 2D6 inhibitorInhibitor0.8966
CYP450 2C19 inhibitorNon-inhibitor0.9248
CYP450 3A4 inhibitorNon-inhibitor0.8506
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9543
Ames testNon AMES toxic0.8434
CarcinogenicityNon-carcinogens0.9238
BiodegradationNot ready biodegradable0.9253
Rat acute toxicity2.6751 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6676
hERG inhibition (predictor II)Inhibitor0.5713
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Lederle laboratories div american cyanamid co
  • Mikart inc
  • Pharmaceutical assoc inc div beach products
  • Pharmaceutical ventures ltd
  • Schering corp sub schering plough corp
  • Nylos trading co inc
  • Vangard laboratories inc div midway medical co
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
Elixiroral2 mg
Elixiroral0.4 mg
Tabletoral2 mg
Tabletoral5 mg
Solutionoral2 mg/5mL
Syruporal2 mg/5mL
Tabletoral2 mg/1
Tabletoral5 mg/1
Prices
Unit descriptionCostUnit
Trihexyphenidyl HCl 5 mg tablet0.37USD tablet
Trihexyphenidyl 5 mg tablet0.36USD tablet
Trihexyphenidyl HCl 2 mg tablet0.26USD tablet
Trihexyphenidyl 2 mg tablet0.18USD tablet
Apo-Trihex 5 mg Tablet0.07USD tablet
Apo-Trihex 2 mg Tablet0.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point258.5 °CNot Available
logP4.49SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.00314 mg/mLALOGPS
logP4.93ALOGPS
logP4.23ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)13.84ChemAxon
pKa (Strongest Basic)9.32ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area23.47 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity93.21 m3·mol-1ChemAxon
Polarizability36.73 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0002-9200000000-2092a098302f5e63b76cView in MoNA
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN04AA01
AHFS Codes
  • 12:08.04
PDB EntriesNot Available
FDA labelDownload (197 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with 1,10-Phenanthroline.
AclidiniumAclidinium may increase the anticholinergic activities of Trihexyphenidyl.
AclidiniumThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Aclidinium.
AlfentanilThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Alphacetylmethadol.
AmbenoniumThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Ambenonium.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Anisotropine Methylbromide.
Atracurium besylateThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Atracurium besylate.
AtropineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Atropine.
BenactyzineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Benactyzine.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Trihexyphenidyl.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Trihexyphenidyl.
BezitramideThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Bezitramide.
BiperidenThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Biperiden.
Botulinum Toxin Type ATrihexyphenidyl may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BTrihexyphenidyl may increase the anticholinergic activities of Botulinum Toxin Type B.
BuprenorphineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Buprenorphine.
ButorphanolThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Butorphanol.
CarfentanilThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Carfentanil.
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Trihexyphenidyl.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Chlorphenoxamine.
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Trihexyphenidyl.
CimetropiumTrihexyphenidyl may increase the anticholinergic activities of Cimetropium.
CodeineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Codeine.
CoumaphosThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Coumaphos.
CyclopentolateThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Cyclopentolate.
DarifenacinThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Darifenacin.
DecamethoniumThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Decamethonium.
DemecariumThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Demecarium.
DesloratadineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Desloratadine.
DexetimideThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dexetimide.
DextromoramideThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dezocine.
DichlorvosThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Dichlorvos.
DicyclomineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dicyclomine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dihydromorphine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Diphenoxylate.
DonepezilThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Donepezil.
DPDPEThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with DPDPE.
DronabinolTrihexyphenidyl may increase the tachycardic activities of Dronabinol.
EchothiophateThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Echothiophate.
EdrophoniumThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Edrophonium.
EluxadolineTrihexyphenidyl may increase the constipating activities of Eluxadoline.
EthopropazineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Ethopropazine.
EthylmorphineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Ethylmorphine.
EtorphineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Etorphine.
FentanylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Fentanyl.
FenthionThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Fenthion.
FesoterodineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Fesoterodine.
GalantamineThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Gallamine Triethiodide.
Ginkgo bilobaThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Glucagon recombinant.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Trihexyphenidyl.
GlycopyrroniumTrihexyphenidyl may increase the anticholinergic activities of Glycopyrronium.
HeroinThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Hexamethonium.
HomatropineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Huperzine A.
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Trihexyphenidyl.
HydrocodoneThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Hydrocodone.
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Trihexyphenidyl.
HydromorphoneThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Hydromorphone.
HyoscyamineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Hyoscyamine.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Trihexyphenidyl.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Trihexyphenidyl.
IsoflurophateThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Isoflurophate.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Trihexyphenidyl.
KetobemidoneThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Ketobemidone.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Levomethadyl Acetate.
LevorphanolThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Levorphanol.
LofentanilThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Lofentanil.
MalathionThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Malathion.
MecamylamineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Mecamylamine.
MefloquineThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Mefloquine.
MemantineThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Memantine.
MethadoneThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Methadyl Acetate.
MethanthelineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Methantheline.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Trihexyphenidyl.
MetixeneThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Metixene.
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Trihexyphenidyl.
MianserinMianserin may increase the anticholinergic activities of Trihexyphenidyl.
MinaprineThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Minaprine.
MirabegronThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Mirabegron.
MorphineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Morphine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with N-butylscopolammonium bromide.
NabiloneTrihexyphenidyl may increase the tachycardic activities of Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Nalbuphine.
NeostigmineThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Neostigmine.
NormethadoneThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Normethadone.
NVA237The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with NVA237.
OpiumThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Opium.
OrphenadrineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Orphenadrine.
OxybutyninThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Trihexyphenidyl.
PancuroniumThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pancuronium.
PentazocineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pentazocine.
PentoliniumThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pentolinium.
PethidineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pethidine.
PhysostigmineThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Physostigmine.
PipecuroniumThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pipecuronium.
PirenzepineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pirenzepine.
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Trihexyphenidyl.
Potassium ChlorideTrihexyphenidyl may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Trihexyphenidyl.
ProcyclidineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Procyclidine.
PropanthelineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Propantheline.
PyridostigmineThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Pyridostigmine.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Trihexyphenidyl.
QuinidineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Quinidine.
RamosetronTrihexyphenidyl may increase the constipating activities of Ramosetron.
RemifentanilThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Remifentanil.
RivastigmineThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Rivastigmine.
ScopolamineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Scopolamine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Scopolamine butylbromide.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Trihexyphenidyl.
SolifenacinThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Solifenacin.
SufentanilThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Sufentanil.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Trihexyphenidyl.
TacrineThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Tacrine.
TapentadolThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Tapentadol.
TiotropiumTrihexyphenidyl may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Trihexyphenidyl.
TolterodineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Tolterodine.
TopiramateThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Tramadol.
TrichlorfonThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Trichlorfon.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Trihexyphenidyl.
TrimethaphanThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Trimethaphan.
TropicamideThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Tropicamide.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Trihexyphenidyl.
TubocurarineThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Tubocurarine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Trihexyphenidyl.
UmeclidiniumThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Umeclidinium.
VecuroniumThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Vecuronium.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Prus AJ, Pehrson AL, Philibin SD, Wood JT, Vunck SA, Porter JH: The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic drug clozapine in rats. Psychopharmacology (Berl). 2009 Apr;203(2):295-301. doi: 10.1007/s00213-008-1262-0. Epub 2008 Aug 7. [PubMed:18685832 ]
  4. Giachetti A, Giraldo E, Ladinsky H, Montagna E: Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine. Br J Pharmacol. 1986 Sep;89(1):83-90. [PubMed:2432979 ]
  5. Tanda G, Katz JL: Muscarinic preferential M(1) receptor antagonists enhance the discriminative-stimulus effects of cocaine in rats. Pharmacol Biochem Behav. 2007 Oct;87(4):400-4. Epub 2007 Jun 2. [PubMed:17631384 ]
  6. Dorje F, Wess J, Lambrecht G, Tacke R, Mutschler E, Brann MR: Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther. 1991 Feb;256(2):727-33. [PubMed:1994002 ]
  7. Freedman SB, Beer MS, Harley EA: Muscarinic M1, M2 receptor binding. Relationship with functional efficacy. Eur J Pharmacol. 1988 Oct 26;156(1):133-42. [PubMed:3208836 ]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Bognar IT, Altes U, Beinhauer C, Kessler I, Fuder H: A muscarinic receptor different from the M1, M2, M3 and M4 subtypes mediates the contraction of the rabbit iris sphincter. Naunyn Schmiedebergs Arch Pharmacol. 1992 Jun;345(6):611-8. [PubMed:1635586 ]
  2. Dorje F, Wess J, Lambrecht G, Tacke R, Mutschler E, Brann MR: Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther. 1991 Feb;256(2):727-33. [PubMed:1994002 ]
  3. Freedman SB, Beer MS, Harley EA: Muscarinic M1, M2 receptor binding. Relationship with functional efficacy. Eur J Pharmacol. 1988 Oct 26;156(1):133-42. [PubMed:3208836 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Bognar IT, Altes U, Beinhauer C, Kessler I, Fuder H: A muscarinic receptor different from the M1, M2, M3 and M4 subtypes mediates the contraction of the rabbit iris sphincter. Naunyn Schmiedebergs Arch Pharmacol. 1992 Jun;345(6):611-8. [PubMed:1635586 ]
  2. Dorje F, Wess J, Lambrecht G, Tacke R, Mutschler E, Brann MR: Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther. 1991 Feb;256(2):727-33. [PubMed:1994002 ]
  3. Freedman SB, Beer MS, Harley EA: Muscarinic M1, M2 receptor binding. Relationship with functional efficacy. Eur J Pharmacol. 1988 Oct 26;156(1):133-42. [PubMed:3208836 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Bognar IT, Altes U, Beinhauer C, Kessler I, Fuder H: A muscarinic receptor different from the M1, M2, M3 and M4 subtypes mediates the contraction of the rabbit iris sphincter. Naunyn Schmiedebergs Arch Pharmacol. 1992 Jun;345(6):611-8. [PubMed:1635586 ]
  2. Dorje F, Wess J, Lambrecht G, Tacke R, Mutschler E, Brann MR: Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther. 1991 Feb;256(2):727-33. [PubMed:1994002 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Bognar IT, Altes U, Beinhauer C, Kessler I, Fuder H: A muscarinic receptor different from the M1, M2, M3 and M4 subtypes mediates the contraction of the rabbit iris sphincter. Naunyn Schmiedebergs Arch Pharmacol. 1992 Jun;345(6):611-8. [PubMed:1635586 ]
  2. Dorje F, Wess J, Lambrecht G, Tacke R, Mutschler E, Brann MR: Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther. 1991 Feb;256(2):727-33. [PubMed:1994002 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23